Neuland Laboratories Ltd
Neuland Laboratories Q2 Results 2026 (FY27): Revenue ₹457.2 Cr, PAT ₹51.1 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Neuland Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26.
As stated in Neuland Laboratories Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Neuland Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. - Profit After Tax (PAT) for Q2FY27 was ₹51.1 crore, down 47.0% YoY. - Diluted EPS for Q2FY27 was ₹39.9 vs. EBITDA for Q2FY27: ₹104.6 crore, down 33.4% YoY - EBITDA Margin for Q2FY27: 22.9%, decreased by 754 basis points YoY - Profit After Tax (PAT) for Q2FY27: ₹51.1 crore, down 47.0% YoY - PAT Margin
From Neuland Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Neuland Laboratories' revenue grow in the September 2026 quarter?
- Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26.
- Profit After Tax (PAT) for Q2FY27 was ₹51.1 crore, down 47.0% YoY.
- Diluted EPS for Q2FY27 was ₹39.9 vs. ₹75.2 in Q2FY26.
- Revenue decrease attributed mainly to operating deleverage despite commercial CMS projects contributing the majority share.
- Q2FY27 standalone revenue declined compared to the prior year quarter.
2 more points from Neuland Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Neuland Laboratories' margins in Q2 FY27?
See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Neuland Laboratories planning?
- Investments highlighted in peptides, R&D, and land acquisition to strengthen capabilities and enable agile expansion (Page 6).
- Acquisition of Unit III plant in FY2018, commercialized in FY2021, with utilization ramping up and expected momentum to continue (Page 22).
- Tangible assets including CWIP grew from Rs. 511.2 Cr in Mar-23 to Rs. 1,185.9 Cr by Sept-26, indicating ongoing capital expenditure (Page 10).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Neuland Laboratories raising money or cutting debt?
See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Neuland Laboratories' order book?
See what Neuland Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Neuland Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neuland Laboratories's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Emcure Pharma (Q2 FY27)
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre
- SPARC (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Key results state
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Neuland Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Neuland Laboratories Ltd Q2 FY27 results?
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. - Profit After Tax (PAT) for Q2FY27 was ₹51.1 crore, down 47.0% YoY. - Diluted EPS for Q2FY27 was ₹39.9 vs. EBITDA for Q2FY27: ₹104.6 crore, down 33.4% YoY - EBITDA Margin for Q2FY27: 22.9%, decreased by 754 basis points YoY - Profit After Tax (PAT) for Q2FY27: ₹51.1 crore, down 47.0% YoY - PAT Margin
What is Neuland Laboratories Ltd share price analysis?
Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 50.5 with a market cap of ₹25,115 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neuland Laboratories Ltd planning capital expenditure?
Investments highlighted in peptides, R&D, and land acquisition to strengthen capabilities and enable agile expansion (Page 6). - Acquisition of Unit III plant in FY2018, commercialized in FY2021, with utilization ramping up and expected momentum to continue (Page 22). - Tangible assets including CWIP grew from Rs.
Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.